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The cell-surface glycoprotein CD44 is involved in a multitude of important physiological
functions including cell proliferation, adhesion, migration, hematopoiesis, and lymphocyte
activation. The diverse physiological activity of CD44 is manifested in the pathology of a
number of diseases including cancer, arthritis, bacterial and viral infections, interstitial lung
disease, vascular disease, and wound healing. This diversity in biological activity is con-
ferred by both a variety of distinct CD44 isoforms generated through complex alternative
splicing, posttranslational modifications (e.g., N- and O-glycosylation), interactions with a
number of different ligands, and the abundance and spatial distribution of CD44 on the cell
surface. The extracellular matrix glycosaminoglycan hyaluronic acid (HA) is the principle
ligand of CD44. This review focuses both CD44-hyaluronan dependent and independent
CD44 signaling and the role of CD44–HA interaction in various pathophysiologies. The
review also discusses recent advances in novel treatment strategies that exploit the
CD44–HA interaction either for direct targeting or for drug delivery.
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Introduction
CD44 is a glycoprotein that is widely expressed on the surface of many mammalian cells, which
includes endothelial cells, epithelial cells, fibroblasts, keratinocytes, and leukocytes (1). Extensive
alternative splicing of nine variable exons and different combinational insertions results in many
distinct CD44 splice variants. CD44 standard is the shortest andmost abundantly expressed isoform;
the other variants are expressed in a cell-specific manner and in the pathophysiology of many
diseases. CD44 has several important physiological functions in cell–cell and cell–matrix inter-
actions including proliferation, adhesion, migration, hematopoiesis, and lymphocyte activation,
homing, and extravasation (2). This diversity in cellular activity is a result of variable expression
of CD44 variants, post-translation modifications such as N- and O-glycosylation, and binding
by a variety of ligands (2). The diversity of isoform expression, posttranslational modifications,
the abundance and spatial distribution of CD44 on the cell surface are likely to be important
Abbreviations: CSC, cancer stem cell; EMT, epithelial–mesenchymal transition; ERM, ezrin–radixin–moesin; GAS, group
A Streptococcus; HA, hyaluronic acid; HCV, hepatitis C virus; HGF, hepatocyte growth factor; HMM, high molecular mass;
ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; LMM, low molecular mass; MMP, matrix metalloproteinase;
milk-HA, HA derived from breast milk; RHAMM, receptor for hyaluronic acid-mediated motility; TLR, toll-like receptor.
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for the regulation of signaling; in particular, because high molec-
ular weight hyaluronic acid (HA) can bind multivalently to CD44
(3–12).
The non-sulfated glycosaminoglycanHA is the principle ligand
of CD44. HA is a polymer of repeating disaccharide units -
glucuronic acid and N-acetyl--glucosamine and can range in
size from millions of Daltons to small oligosaccharides. The size
of the HA is important for its physiological functions. HA of a
high molecular mass (HMM) can naturally bind multivalently
to more surface receptors across a larger area of the cell than
low molecular mass (LMM) HA, and this difference in the num-
ber of bound HA receptors allows different sizes of HA to have
different signaling effects. HMM HA is typically >500 kDa, and
LMM HA is typically between 10 and 500 kDa. Because of the
lack of a standard size for HMM and LMM HA, this review
will list the molecular mass of the HA fragments and will refer
to the size as HMM or LMM based on the classification used
by study authors. HA is a major component of tissue matrices
and fluids and is involved in a variety of physiological functions
such as maintaining tissue hydration and osmotic balance, cell
proliferation, adhesion, andmigration (13).Much of its regulation
of cellular function is mediated through CD44 and RHAMM
signaling, although it has been shown to affect toll-like receptor
signaling as well. Since HA also plays a role in the assembly
and remodeling of extracellular matrix, these activities of HA
are also likely to affect cellular function. HA is synthesized by
HA-synthases HAS1, HAS2, and HAS3 in humans. HA synthesis
occurs on the cytoplasmic side of the plasma membrane and it is
then expelled into the extracellular space. HA is synthesized by
many cells but mesenchymal cells are the major source of HA. HA
is degraded by hyaluronidase family of enzymes, and the well-
studied hyaluronidases are HYAL1, HYAL2, and PH-20/SPAM1
(13). Hyaluronidases degrade HA by hydrolyzing the linkages
between the -glucuronic acid and N-acetyl--glucosamine dis-
accharides.
CD44 has been implicated in a number of diseases such as
cancer, arthritis, interstitial lung disease (ILD), vascular dis-
ease, wound healing, and infections by pathogens. CD44–HA
signaling has been found be involved in the pathophysiologies
of both malignant and non-malignant diseases. While several
excellent reviews have been focused on CD44–HA signaling
and its implications in cancer (3–12), this review focuses on
both HA-independent (mainly) and HA-dependent functions of
CD44 in the pathophysiology of various diseases. In addition, the
review discusses various strategies used for targeting of CD44,
and CD44/HA-based therapeutic interventions and devices for
targeted imaging and treatment options.
CD44–HA Signaling and Human Disease
Infections
The importance of CD44–HA signaling has been implicated in a
number of studies. CD44–HA signaling plays important roles in
host defense against invading pathogens, specifically in activation
and migration of lymphocytes (14). HA signaling through CD44
has also been linked to generation of antimicrobial peptides (15).
Several other studies have shown that CD44–HA signaling can be
utilized by pathogens for progression of infections and resulting
complications.
CD44–HA signaling has long been known to play a role in
host defense through activation, homing, rolling, and extravasa-
tion of lymphocytes into inflammatory sites (16, 17). A recent
study suggests that CD44–HA signaling also contributes to host
defense during the early stages of infancy. CD44–HA signaling
induces human β-defensin 2 (HβD2), which, in turn, enhances
antimicrobial defense in the intestinal epithelium (15). The study
found that HA derived from breast milk (milk-HA), at 2-week
intervals up to 6-month postpartum when HA concentrations
were highest, induced production of HβD2 in HT-29 cells, and
mice fed with milk-HA also increased expression of MuβD3,
the mouse ortholog of HβD2. The authors also fed CD44 / ,
TLR4 / , orwild typemicewithmilk-HAand found thatMuβD3
expression was greatly reduced in CD44 /  or TLR4 /  mice
when compared to wild type mice; HT-29 cells pretreated with
anti-CD44 antibodies also showed inhibition of HβD2 expression
upon treatment with milk-HA. Salmonella infection was shown
to be greatly decreased in cells treated with milk-HA when com-
pared to milk-HA pretreated with hyaluronidase. These results
suggest that CD44–HA signaling is important in the establishment
of intestinal epithelium resistance to invading pathogens during
early infancy. In a previous study by the above-mentioned group,
addition of LMM HA averaging 35 kDa was shown to upregulate
HβD2 inHT-29 cells and inmice in a size-specificmanner; similar
expression was observed upon treatment in combination with
HMM HA (2MDa), but not with HA-2M alone (18). Interest-
ingly, HA-35 up-regulation of HβD2 was shown to be toll-like
receptor 4 (TLR4) dependent but not CD44 dependent. In the
2013 study, HβD2 up-regulation by milk-HA was both TLR4
and CD44 dependent. The 2013 study did not address whether
breast milk HA of different sizes had any effect on HβD2 levels,
and in the 2011 study CD44 dependency was not ascertained
with HA-35 and HA-2M combination treatment. Other studies
have also reported up-regulation ofHβD2 and other antimicrobial
peptides upon treatment with LMM HA (<200 kDa) in a CD44-
independent manner (19, 20). TLR4 has been shown to complex
with CD44 upon treatment with HA (21). Perhaps these studies
together point to independent yet complementary mechanisms
by which LMM HA (2.5 kDa) signals through TLR4, which may
complexwithCD44 in the presence ofHMMHA(10MDa),which
has been shown to increase CD44 clustering (22).
Bacterial Infection
Group A Streptococcus (GAS) utilizes an intriguing method to
escape host defenses and adhere tomammalian cells. The capsular
polysaccharide of GAS comprises HMMHA that is similar in size
to the HA synthesized by mammalian cells and tissues (23). It has
been shown thatGAS adheres to human keratinocytes through the
binding of capsular HA polysaccharides to CD44 (24). An in vivo
study by the same laboratory evaluated the importance of CD44
expression for GAS infection of the pharynx using C57BL/6 mice
and K5-CD44 transgenic mice that expressed a CD44-antisense
transgene (25). In this study, transgenic mice with reduced CD44
expression showed significantly lower GAS infection than mice
with wild type CD44 expression. GAS infection was also reduced
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by treatment with anti-CD44 antibodies and addition of exoge-
nous HA. This study further reinforced the idea that CD44–HA
binding is important for GAS infection.
Amore recent study evaluated the importance of the molecular
mass of HA for macrophage-mediated phagocytosis of GAS in
both in vitro and in vivo murine models (26). In this study,
ingestion of GAS by macrophages was inhibited by addition
of HMM HA (i.e., 800–1200 kDa), while the addition of LMM
HA (i.e., 25–75 kDa) increased GAS internalization. Similarly,
GAS survival was increased in murine blood in the presence of
HMM HA. Interestingly, the study showed that treatment with
hyaluronidase, an enzyme that degrades HA in small fragments
increased internalization of GAS by macrophages. The internal-
ization of GAS bymacrophages was not present in transgenicmice
expressing a CD44-antisense transgene even in the presence of
LMM HA, demonstrating that CD44 expression on macrophages
is required for GAS internalization. The HMMHA in the capsular
polysaccharide of GAS mimics tissue homeostasis and allows
GAS to escape detection by the host immune system. Contrar-
ily, LMM HA (>200 kDa) may function as an endogenous dan-
ger signal, activating the innate immune system (27). CD44 has
also been shown to function as a primary phagocytic receptor
via HA signaling (28). Taken together, LMM HA may mediate
a signaling cascade that leads to macrophage recruitment and
facilitate phagocytosis of GAS by binding to CD44 expressed on
macrophages. These studies suggest that CD44–HA signaling is
important for GAS infection. Whether CD44–HA signaling aids
in host defense of GAS infection depends on the molecular mass
ofHA, further exemplifying the intricacy ofCD44–HA interaction
and signaling in disease pathophysiology.
Helicobacter pylori infection is the major risk factor for gastric
cancer, which is the second leading cause of cancer-related death
in the world (29). Chronic infection by H. pylori has been shown
to result in atrophy of acid-secreting parietal cells, which leads
to increased proliferation of stem/progenitor cells in the isthmus
(30). The increased proliferation of isthmus stem cells is believed
to be one of the contributing factors that lead to neoplasia. A
recent study showed that proliferation of isthmus stem cells after
atrophy of parietal cells is a result of a signaling cascade that
involves CD44–HA-mediated activation of ERK and STAT3 (31).
The study showed that in CD44 knockout mice, or mice treated
with PEP-1, an inhibitor of CD44–HA interaction, there are signif-
icantly less proliferating isthmus stem cells than in wild type mice
after infection withH. pylori. CD44–HA signaling was also shown
to be important in the progression toward gastric cancer after a
complication of H. pylori infection. It would be interesting to see
the impact ofHA size in isthmus stem/progenitor cell proliferation
after parietal cell atrophy. Parietal cell atrophy possibly leads to
breakdown of HA to small fragments, which then induce to pro-
proliferative signaling cascades; in that case, addition ofHMMHA
may serve to restore homeostasis and inhibit proliferation.
Pneumonia is caused by infection of lung parenchyma by
numerous bacteria and is a leading cause ofmorbidity andmortal-
ity. A number of studies have implicated CD44 in the progression
of bacterial infection and in the amelioration of lung inflam-
mation in pneumonia models. The role of CD44 in the acute
phase (6 h after infection) of pneumonia caused by Escherichia coli
and Streptococcus pneumoniae differed significantly as reported
in a previous study (32). The study showed that when com-
pared to wild type mice, E. coli-induced pneumonia in CD44-
deficient mice causes increased lung inflammation, as evidenced
by increased neutrophil accumulation, migration, and increased
mRNA levels of inflammatory genes. However, such was not the
case in S. pneumoniae-induced pneumonia. The differences in E.
coli versus S. pneumoniae-induced pneumonia may be because
the latter expresses hyaluronidase, which breaks down HA. This
would decrease CD44–HA-mediated signaling and the down-
stream induction of inflammatory pathways. The study found
that HA levels were decreased in the lungs after Streptococcal
infection. A lower dose of infection with S. pneumoniaemay have
given a clearer picture ofCD44’s role in the inflammatory response
to infection by this bacterium. A later study explored this scenario
and found transient increases in inflammation in CD44 knockout
mice at lower doses of S. pneumoniae-induced pneumonia (33).
This study also looked at the role of CD44 in prolonged lung
infection (10 days) by Streptococcus. The study found that CD44
knockout mice had less bacterial outgrowth and dissemination,
and higher survival rates compared to wild type mice at lethal
doses. Another study by the same laboratory found similar results
for Klebsiella pneumoniae-induced pneumonia (34). Together
these studies show that CD44 signaling is important for reducing
inflammation in the lungs, and may increase bacterial dissemina-
tion and outgrowth. It is possible that CD44 anti-inflammatory
signaling plausibly decreases the clearing of bacteria, and there-
fore, allows for their growth and dissemination to other sites. To
this effect, CD44 has been previously shown to play an important
role of resolving lung inflammation (35).
Viral Infection
CD44–HA signaling has also been shown to play an important
role in the course of HIV and hepatitis C (HCV) infections. HIV
virions have been shown to acquire functional CD44 from host
cells (36–38). In a recent study, CD44–HA signaling was shown to
affect the infectivity of HIV in unstimulated primary peripheral
blood mononuclear cells, unstimulated CD4+ T cells, and M7-
Lue cells (39). In this study, HIV with virions expressing CD44
showed decreased infectivity of unstimulated peripheral blood
mononuclear cells, unstimulated CD4+ T cells, and M7-Lue cells
when treated with exogenous HA. Interestingly, this decrease of
infectivity was not seen in Jurkat-E6.1 cells, which do not express
CD44norwas this decrease in infectivity observed usingHIVwith
virions that did not express CD44. The study also showed that
HIV infectivity was increased upon addition of hyaluronidase,
suggesting that endogenous HA plays a protective role against
HIV infection. Cells treatedwith hyaluronidase had decreasedHA
at the cell surface and were five times more susceptible to HIV
infection than cells not treated with hyaluronidase. The study also
showed that exogenous HA reduces HIV infectivity of CD4+ T
cells by reducing the activation of protein kinase C-α via CD44.
These results suggest that CD44–HA interactions are important
for HIV infection and that addition of exogenous HA may inter-
fere with this interaction. Furthermore, this inhibition of infec-
tivity by exogenous HA may be mediated by the inhibition of the
protein kinase C-α pathway and is dependent on the thickness of
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HA at the cell surface. It would be interesting to see if these results
can be replicated in vivo, and whether the reduction of infection
is dependent on the average molecular weight of exogenous HA
and/or HA at the cell surface.
The expression of gamma interferon-inducible protein 10 (IP-
10) has been shown to be elevated in chronic HCV patients and
is a predictor of treatment outcome (40). In a study aimed at
elucidating what role TLRs play in the production of IP-10 in cells
infected by and actively replicating HCV, CD44–HA signaling
was shown to be involved in IP-10 production (41). In this study,
CD44 expressionwas found to be increased in cells harboring viral
replicons. Blocking viral replication led to a reduction in CD44
expression. Furthermore, HA stimulation of cells with actively
replicating HCV virus increased IP-10 production; contrarily,
knockdown of CD44, TLR2, or MyD88 greatly reduced IP-10
production. These results suggest that in infected cells, HCV
induces IP-10 production via CD44–TLR2–MyD88 interactions.
This study also links HCV replication to increased expression
of CD44. An interesting follow-up study may elucidate whether
HCV repliconmediated up-regulation of CD44–HA signaling and
increased production of IP-10 leads to leukocyte recruitment and
the establishment of chronic inflammation in the liver, leading to
HCV-associated fibrosis, cirrhosis, and hepatocellular carcinoma.
These studies further illustrate the complex roles that
CD44–HA signaling plays in human infections by pathogens.
In the case of HIV infection, it appears that exogenous and
endogenous HA protect host cells from infection in a CD44-
dependent manner. The opposite is seen in the case of HCV
infections; overexpression of CD44 by HCV replicating cells
may contribute to overproduction of IP-10, exacerbation of
liver damage, and to a poor treatment outcome in chronic HCV
patients.
Interstitial Lung Disease
CD44–HA signaling has been implicated in the progression of
ILD, which includes idiopathic pulmonary fibrosis (IPF) and
systemic sclerosis associated ILD. CD44–HA signaling was shown
to play a role in the development of progressive lung fibrosis
by activation of myofibroblasts with an acquired invasive phe-
notype (42). In this study, HAS2-overexpressing transgenic mice
showed increased deposition of HA and accumulation and up-
regulation of CD44 mRNA and protein in lung myofibroblasts
after bleomycin-induced lung injury, resulting in increased lung
fibrosis and fatality. However, HAS2 knockout mice did not have
increased HA deposits, up-regulation of CD44 or myofibroblast
accumulation, and did not show signs of pulmonary fibrosis.
Interestingly, the study also found that fibroblasts isolated from
HAS2-overexpressing transgenic mice showed increased invasive
capacity inMatrigel™when compared to controls and HAS2-null
mice. This increase coincided with increased matrix metallopro-
teinase (MMP) levels and decreased tissue inhibitors of metallo-
proteinases levels in HAS2-overexpressing transgenic mice and
also in the fibroblasts from IPF patients. The results from this
study suggests that HAS2 overexpression, post-lung injury, leads
to dysregulated CD44–HA signaling, resulting in a signaling envi-
ronment conducive to fibroblast activation and invasion leading
to the development of IPF. It would be important to determine
if this HA-mediated signaling environment is dependent on the
molecular weight of HA. For example, addition of exogenous HA
of specific mass to isolated IPF fibroblasts may further elucidate
the nature of CD44–HA signaling in progression of lung fibrosis.
Another important study would be to evaluate the respective
roles of CD44 and receptor for hyaluronic acid-mediated motil-
ity (RHAMM), which are expressed on fibroblasts (43), in the
development of IPF.
A recent study evaluated the relationship and function of
CD44v6, TGF-β1, and hepatocyte growth factor (HGF) in ILD
(44). The study found that lung fibroblasts from bleomycin-
treated mice and from ILD patients had elevated levels of CD44v6
and c-Met, both of which were expressed upon TGF-β1 induc-
tion. CD44v6 was shown to increase collagen-1, and therefore,
enhance lung fibrosis. TGF-β1 induction and lung fibrosis were
shown to be abolished by HGF. One caveat of this study is that
HGF levels are increased in fibroblasts from ILD patients, which
is contradictory to the finding that HGF negatively regulates
TGF-β1 induction, and therefore inhibits lung fibrosis. However,
HGF concentrations in ILD fibroblasts were much lower than the
concentrations used in the study.
In summary, these studies reveal a causative role of CD44 and
its isoform CD44v6 in ILD. Furthermore, HA is important in the
progression of fibroblast invasion and lung fibrosis. Interestingly,
a recent study found that disruption of the HA matrix or inhibi-
tion of HA synthesis actually increased deposition of fibronectin
and collagen-1 by myofibroblasts in which TGF-β1 was induced,
and HAS2 expression was increased in these myofibroblasts (45).
These results together suggest that disruption of endogenous HA
or tissue matrix homeostasis may cause dysregulated deposition
of fibronectin and up-regulation of HA by fibroblasts that have
constitutively active TGF-β1 signaling. Up-regulation of HAS2
expression in these fibroblasts leads to aberrant CD44–HA signal-
ing, whichmay lead to activation of more fibroblasts with invasive
phenotypes.
Wound Healing
Hyaluronic acid concentrations in tissues undergoing wound
repair are elevated for several weeks after injury (46). The primary
source of this HA is keratinocytes, but other tissue specific cells
can produce the glycosaminoglycan as well. One of the functions
of HA in wound repair is to provide a scaffold for cell migration
toward injury sites such as hepatic stellate cells migrating toward
a liver epithelial injury utilizing CD44v6 (47).
A recent study in a rat bladder regeneration model found that
HA deposition in a regenerating bladder after partial cystectomy
was required for proper wound healing (48). CD44 expression
also increased as the wound healed, mimicking the deposition
pattern of HA. The function of the HA–CD44 interaction could
simply be to provide a scaffold for tissue repair, but other research
shows that LMM and HMM HA found in sites of injury may
have direct effects on regeneration. In a mouse acute myocardial
infarction model, it was found that IL-6 production in the heart
induced HA synthesis, and that HA was required for the differ-
entiation of fibroblasts into myofibroblasts (49). HA binding to
CD44 also leads to the production of MCP-1 and CCL5, which
recruit neutrophils to the heart and establish a cardio-protective
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environment. It has previously been shown thatCD44 andERK1/2
complexes exist in fibroblasts and are required for scratch repair
(43).
It is not just the presence of HA and CD44 that shape the
wound healing process, but also the size and longevity of the
HA fragments. HMM HA (>106 Da) is typically present in pre-
natal wound healing, resulting in healing with minimal inflam-
mation and scar formation (50–53). HA oligosaccharides (six to
eight oligomers) are typically present in adult wound healing,
and results in inflammation and scar formation (54–57). If HA
oligomers are not removed from tissue during wound repair then
tissue destruction occurs from unending fibrosis and inflamma-
tion (21). The negative impact of prolonged accumulation of
LMMHAonwound repair is primarily caused by its ability to bind
to and activate TLR4. In amouse sterile injurymodel, it was found
that MD-2, a TLR4 accessory protein that increases TLR4’s ability
to bind lipopolysaccharide, and CD44 worked together to bind
LMM HA on monocytes (21). This prolonged TLR4 signaling-
induced production of TGF-β2 and MMP-13, resulting in tissue
damagemuch the same as if lipopolysaccharide was present in the
wound. This finding expands upon earlier research showing that
CD44 can associate withMyD88 signaling complexes and TLRs in
lipid rafts (58).
A recent study using normal human dermal fibroblasts also
shows that LMM HA (4.3 kDa) induces the production of IL-
6, IL-8, CXCL1, CXCL2, CXCL6, and CCL8 whereas, HMM
HA (1.1 106 Da) can inhibit the production of IL-6 and IL-8,
indicating potential TLR and MyD88 involvement (59). Closer
examination of the effect of specific sizes of HA has revealed
that six oligomer fragments of HA are capable of promoting
wound closure, accumulation of M2 macrophages, and produc-
tion of TGF-β1 without inducing myofibroblast differentiation in
a scratch wound repair model (60). Conversely, HA fragments of
40 kDa were found to actively inhibit wound closure and cause the
accumulation and differentiation of myofibroblasts.
In conclusion, HA binding to CD44 is required for proper
wound healing, but the size and longevity of the HA has a large
effect on the outcome. Future research on the size and location
of exogenous HA that can be used to aid in wound healing will
be of great medical benefit. Surgical scarring could be a thing
of the past if small oligomers of HA could be introduced into a
wound after incision, but the fragmentswould need to have a short
biological half-life in order to prevent fibrosis and inflammation
from occurring.
CD44–HA Signaling and Cancer
CD44 signaling has been shown to be important in cancer metas-
tasis and tumor growth, but can be broken down into two
primary areas. HA-independent signaling relies on interactions
between CD44’s intracellular domain and cytoskeletal proteins or
membrane associated kinases. HA-dependent signaling relies on
two CD44 molecules being cross-linked, allowing other CD44-
associated signaling proteins to interact with each other. Further,
CD44 is used as a marker for cancer stem cell (CSC) detection in
a variety of cancers without much research into the function of
CD44 in stem cells beyond adhesion.
HA-Independent Signaling
CD44 signaling that isHA independent is largely reliant onCD44’s
position in lipid rafts. Association between CD44 and other sig-
naling proteins are often regulated through CD44’s interaction
with ezrin–radixin–moesin (ERM) protein family members that
initiate association with cytoskeletal elements.
A recent study examines the role of CD44 in Wnt pathway
signaling using Xenopus embryos (61). In this study, CD44 was
found to be a positive regulator of Wnt pathway activation by
associating with LRP6. In this model, a comparison between
various CD44 splice variants showed that all isoforms of CD44
are capable of association with LRP6, but some isoforms such as
CD44v6 may be associated with higher levels of Wnt activity. The
Schmitt study also shows that while the extracellular domain of
CD44 interacts with LRP6, the intracellular domain interacts with
and coordinates a protein complex with the rest of the Wnt path-
way downstream targets through cytoskeletal arrangement. HA-
independence was verified in this study by utilizing hyaluronidase
treatment and an anti-CD44 antibody that blocks the HA binding
domain. This recent finding is significant because CD44 vari-
ant isoform expression is correlated with tumor progression in
colorectal cancer and high Wnt activity, which is the signaling
pathway known to control colorectal cancer progression (62–64).
A similar signaling pathway is found in hepatoma, colon ade-
nocarcinoma, and cervical carcinoma cells, which results in the
ability to scatter and spread (65). The Orian-Rousseau study illus-
trates the fact that CD44v6 is required for c-Met activation upon
HGF stimulation. The extracellular domain of CD44v6 is required
for autophosphorylation of c-Met, but the intracellular domain
is required for further downstream signaling. The interactions
between CD44’s intracellular domain and ERM protein family
members facilitate the association of GRB2 and SOS. In this way,
CD44v6 serves as a linkage between the cell surface c-Met protein
and the MAPK/ERK pathway members that are associated with
the cytoskeleton. Recently, it was discovered that CD44v6 is also
required for internalization of activated c-Met so that c-Met can
be recycled or degraded (66). Hasenauer et al. showed that the
Met receptor was linked to the actin cytoskeleton via CD44 and
Ezrin, which allowed for endocytosis of activated Met in order
to sustain regulated cell migration and branching. ERM protein
family interaction with CD44 and the cytoskeleton can be dis-
rupted by decreasing the amount of available phosphatidylinositol
4,5-bisphosphate (67). This finding can be exploited depending
on the context through activation or inhibition of phospholipase
C proteins, which decrease the amount of phosphatidylinositol
4,5-bisphosphate available upon activation.
Another recent novel finding is the association of CD44 with
PP2A, a phosphatase known to dephosphorylate Raf, MEK, and
Akt (68). In this study, EL4 T cell lymphoma cells were found
to show decreased ERK phosphorylation and increased apoptosis
upon ligation of CD44 with an anti-CD44 antibody that also
blocks the HA binding domain. The CD44 ligation induced the
binding of PP2A to the intracellular domain of CD44 as well
as PP2A’s activation. The activated PP2A then dephosphorylates
ERK1/2 without causing its degradation, resulting in activation
of the mitochondrial death pathway. It is not known if the
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interaction of PP2A and CD44 requires the ERM protein family
or cytoskeleton.
In summary, CD44 standard and variant isoforms are closely
associated with many signaling pathway proteins that drive
tumor development and progression in many types of cancer.
These associations exist and activate signaling cascades without
direct binding of CD44 to its ligand, highlighting the impor-
tance of CD44 as a co-receptor and emphasizing its importance
and potential in targeted cancer therapy. The findings dis-
cussed above may not tell the complete story of HA-independent
CD44 signaling. Experiments often rely on antibodies against
the HA binding domain of CD44 and hyaluronidase treatment
to study HA-independent CD44 signaling, but it is not pos-
sible to completely eliminate endogenous HA. Hyaluronidase
treatment alone may simply cleave HA within the extracellular
matrix and induce oligomer binding to CD44. Blocking anti-
bodies compete with endogenous HA for receptor binding, and
may not completely prevent HA binding; these antibodies may
also cross-link CD44 on the cell surface in a similar man-
ner to HA binding, resulting in a phenomenon that could be
observed with exogenous HA. Truncated CD44 expression or use
of CD44 knockout mice are two potential ways to verify HA-
independence, but this proves a complicated feat to perform in
cell lines that already express high levels of CD44 and human
samples.
HA-Dependent Signaling
CD44 does not exist without ligand binding capabilities, and
the interaction between CD44 and its major ligand HA induces
signal transduction as well (Figure 1). HMMHA (>950 kDa) has
been shown to promote proliferation of decidual cells during the
early stages of pregnancy by activating the PI3K/Akt and ERK1/2
signaling pathways (69). Several recent studies have also focused
on the function of CD44 isoforms in various types of cancer upon
the addition of HA.
A recent study has shown that when fibroblasts are allowed
to adhere onto a surface coated in HA; CD44, CD36, PP2A,
and CDK9 are upregulated (71). PP2A expression increases
in these fibroblasts, mimicking what was seen in T cell lym-
phoma in the Rajasagi study. The Yang study shows that natu-
ral conditions resulting from HA polysaccharides binding and
cross-linking CD44 on fibroblast surfaces increase the expres-
sion of PP2A. The Rajasagi paper demonstrates PP2A associ-
ation with CD44 through therapeutic intervention with anti-
CD44 antibodies and no exogenous HA. One of the more thor-
oughly investigated aspects of HA-dependent CD44 signaling
is in its role in facilitating epidermal growth factor receptor
signaling.
The above two studies illustrate the fact that the signaling
pathways seen in HA-dependent CD44 signaling are almost iden-
tical to those seen in HA-independent signaling. CD44 isoforms
are associated with downstream pathway molecules such as PI3-
kinase, SRC, SOS, andGRB2 through the ERM family (65, 72–74).
This association allows for CD44 in lipid rafts to essentially bring
all of the necessary signaling components of multiple pathways
with them.When HA binding to CD44 occurs it may bring CD44
in close proximity to signaling receptors such as ErbB2, EGFR,
FIGURE 1 | HA-dependent CD44 signaling. HA binding to cell surface
CD44 and RHAMM triggers a variety of signaling events, including complex
formation between CD44 and co-receptors such as c-Met, EGFR, and TGF-β
receptors, and activation of downstream effectors such as Akt, PI3K, PP2A,
ERK1/2, and Ras/Raf/Rac. These signaling events culminate in the
expression of a variety of inflammatory cytokines and activation of a feedback
loop continuing cell surface expression of CD44/RHAMM. By inducing these
signaling events and downstream effectors, HA–CD44 signaling drives
proliferation, invasion, cytoskeletal rearrangement, and angiogenesis, which
lead not only to normal cell functions such as fibroblast migration, wound
healing, and immune cell function but also to tumor growth and
progression (70).
or TGF-β type 1 receptors, allowing for direct association and
interaction between receptors and their signaling complexes in a
tightly localized lipid raft (75–78).
Recent work has highlighted novel areas of CD44–HA inter-
action. A study in MDA-MB-468 breast cancer cells has shown
that CD44 cross-linking and signaling upon HA binding activates
c-Jun nuclear translocation (79). Activated c-Jun induces the tran-
scription of microRNA-21, which increases the amount of Bcl-
2 and upregulates inhibitors of the apoptosis family of proteins.
TheHA-dependent CD44 signaling also induces chemoresistance.
This finding can help transition CD44 research from the more
classical viewpoint that it serves as a marker without much func-
tional role into a biomarker that has a known and exploitable
function.
CD44 does not bind to HA alone. RHAMM also binds to HA
in a complex with CD44 in order to facilitate signal pathway
involvement. In prostate cancer cells, HA and HA fragments
were shown to induce growth factor receptor signaling, includ-
ing the PI3K/Akt pathway (80, 81). However, knockdown of
both RHAMM and CD44 with siRNAs was required to achieve
complete inhibition of HA-mediated signaling events. RHAMM,
CD44, and ERK1/2 are in a signaling complex and can be co-
immunoprecipitated from MDAMB231 and Ras-MCF10A breast
cancer cells; this complex promotes sustained high basal motility
(82). The Hamilton study also used anti-RHAMM antibodies to
block MEK activation, illustrating the important of RHAMM as
a co-receptor with CD44. RHAMM has also been shown to be
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required for CD44–HA signaling in head and neck cancer and
cementifying fibroma (77, 83).
CD44 as a Cancer Stem Cell Marker
CD44 has lately emerged in CSC or cancer initiating cell studies
as a biomarker. A large number of CSC studies use CD44 stan-
dard or variant isoform expression as a typical marker (84–87).
Current research is focusing on the role of CD44 signaling during
epithelial–mesenchymal transition (EMT).
A recent study using mouse pancreatic tumor cells shows that
CD44 is expressed on a specific population of pancreatic cancer
cells (88). CD44 expression drives up-regulation of Snail1, result-
ing in increased MT1-MMP, which facilitates invasion. MT1-
MMP is also known to directly associate with CD44 at the cell
surface, where CD44 aids in the recycling of MT1-MMP so that
cells can continue to degrade the extracellular matrix (89, 90).
An in-depth look at current literature for CD44 and EMT
reveals that most studies use CD44 as a marker instead of a
potential mechanism. A recent study shows that microRNA-106b
is upregulated only in CD44+ gastric cancer cells undergoing
EMT and that TGF-β signaling was also elevated (91). Coupled
with the established link between CD44 expression and other
microRNAs, as well as the relationship between CD44 and TGF-
β, one could make the case for further study into the potential
for CD44 expression to be the cause of this phenomenon rather
than a simple marker for EMT. A recent study of a mouse mam-
mary epithelial cell line (NMuMG) and a triple negative human
breast cancer cell lineMDAMB231 shows that CD44 couples with
VCAM-1 in order to initiate EMT as well as chemoresistance
(74). Physical association betweenVCAM-1 and CD44 resulted in
increased expression of ABCG2, a drug efflux pump responsible
for inducing resistance to chemotherapy (92).
A recent study of human primary prostate cancer tissues and
lymph node metastases revealed that CD44v6 was highly upreg-
ulated in tumors and CSCs (93). Knockdown of CD44v6 with
siRNA in DU145, PC3M, and LNCaP cells increased sensitivity
to doxorubicin, methotrexate, docetaxel, and paclitaxel. CD44v6
knockdown also reduced tumor sphere formation and prolifer-
ation. The Ni study also showed that CD44v6 was responsible
for activation of PI3K, Akt, mTOR, and Wnt signaling pathways,
which were driving EMT in these cell lines.
A study by Kinugasa et al. also showed that CD44 was impor-
tant formaintaining the stemness of cancer cells, but in an indirect
manner (94). Cancer-associated fibroblasts from B16 melanoma
tumors were found to express high levels of CD44, and co-culture
of human colorectal cancer HT29 cells and human lung carci-
noma LLC1 cells with these fibroblasts resulted in drug resistance,
tumor sphere formation, and tumor growth. Cancer-associated
fibroblasts generated from CD44 knockout mice did not result in
a sustained CSC state. The pathways regulated by CD44 in these
fibroblasts have yet to be determined, but the studies from Ni
and Kinugasa illustrate the complex nature of CD44 signaling in
cancer.
Several studies do not directly examine the role of CD44
in CSCs, but focus on its absence or presence in response to
gene silencing and other treatments. When STAT3 is knocked
down in MCF7–HER2 breast cancer cells, the expression of CSC
markers CD44, Oct-4, and Sox-2 was downregulated, resulting
in decreased tumor sphere formation (95). Potential CD44–PI3K
andCD44–ERK signalingwould be eliminated in the case ofCD44
downregulation, which could explain the absence of tumor sphere
formation in these cells. Treatment of human T24-L bladder
cancer cells with Silbilin results in a decrease in CD44 expres-
sion, spheroid colony formation, side population presence, and a
reversal of EMT (96). Silbilin also inhibited β-catenin and ZEB1
signaling, possibly through inhibition of GSK3β phosphorylation.
As discussed above, CD44 is involved in the Wnt pathway and
therefore β-catenin, but CD44 can also positively and negatively
regulate GSK3β (83, 97). Therefore, CD44 may be a central
molecule in several signaling pathways, but many studies still
examine it only as a marker of stemness.
In conclusion, changing the perspective of CD44 expression
from that of a simple marker to a protein, which causes cancer
growth and progression, will pave the way for future therapeutic
intervention. The studies highlighted above that focused on the
role of CD44 as a signalingmolecule rather than amarker without
a function, are a fragment of the potential research yet to be
unlocked. Continued discovery of novel roles for CD44 in cancer
development will help expand the mounting potential of CD44 as
a prime therapeutic target.
Targeting HA Receptors
Since the discovery that HA receptor, CD44 is a stem cell marker,
targeting of CD44 for anti-cancer therapy has been attempted
using DNA vaccines, anti-CD44 monoclonal antibodies, and
nanoparticle-mediated delivery of CD44siRNAs. In addition, HA-
coated nanoparticles or anti-CD44 conjugates have been used to
target CD44+ cells for therapy.
CD44 Vaccines
CD44 cDNA or targeting of CD44-expressing cells has been used
to generate tumor immunity in experimental models. A recent
study has examined the concept of “foreignizing” tumor cells by
specifically delivering foreign antigens to target CD44hi tumor
cells using a polymeric ovalbumin (foreign antigen) and HA
delivery system (98). In this study, the polymeric conjugate was
accumulated on CD44hi tumor cells. Furthermore, the surface
class IMHCantigens on these tumor cells displayed anOVA257–264
peptide.When these tumor cells were injected inmice, whichwere
immunized with a vaccinia virus expressing ovalbumin, tumor
growth was reduced due to OVA257–264 peptide specific cytotoxic
T-lymphocytes. CD44 cDNA vaccination also has been delivered
by implanting virtual lymph nodes in immunocompetent animals
to generate anti-CD44 antibodies. These virtual lymph nodes
are generated by subcutaneous injection of a silicon tube filled
with a segment of hydroxylated-polyvinyl acetate wound dress-
ing sponge in which CD44-standard or CD44-variant cDNA is
inserted. Using this model, CD44-standard form vaccination was
shown to reduce autoimmune encephalomyelitis (99).
In a similar approach of using virtual lymph nodes, the
effects of CD44 vaccination on tumor growth and lung metas-
tasis were evaluated in a mouse mammary adenocarcinoma
model (DA3 cells). Vaccination was achieved by injection of
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virtual lymph nodes loaded with human CD44 variant (v3–10)
or CD44-standard cDNAs. Immunized animals expressed anti-
bodies against human CD44 variant and CD44-standard forms.
The vaccination against CD44 variant (v3–10) was more effective
than vaccination with the CD44-standard isoform in eliminating
tumor growth in 75% of the vaccinated mice and slowed tumor
growth in the remaining animals. Furthermore, metastasis was
eliminated in all animals. Since CD44-standard form did not
generate the same immunological response against tumors, it sug-
gested that CD44 variant (v3–10) and not CD44s was functional
in promoting tumor growth and metastasis in DA3 cells. It is
noteworthy that in this study human CD44 (hCD44) was injected
in order to break the tolerance to mouse CD44 (mCD44). There-
fore, mouse CD44 (mCD44) should be injected to human patients
to break CD44 tolerance, but this is not practical in clinical set-
ting (100). The virtual lymph node and CD44 cDNA approach
has also been used to induce resistance to insulin-dependent
diabetes. In this study, both CD44 standard and CD44v3–v10
cDNAs induced resistance to diabetes to the same extent, and
the resistance was antibody mediated (101). As in the study by
Wallach-Dayan et al., this study also used human CD44 cDNA
to break the self-tolerance to mouse CD44, and the use of mouse
CD44 cDNA did not generate a humoral response. This may
be a likely reason as to why the virtual lymph node approach,
involving CD44 cDNA vaccination has not been translated into
clinical trials. Another approach for CD44 vaccination involves
dendritic cell vaccination. In the B16 melanoma lung metasta-
sis model, dendritic cells were pulsed with anti-CD44 coated
apoptotic B16 melanoma cells. Such opsonized B16 melanoma
cells were readily endocytosed by dendritic cells. Following vac-
cination of mice with dendritic cells, animals were challenged
with subcutaneous injection of B16 cells. In vaccinated animals,
both lung metastasis (50% reduction) and tumor growth were
inhibited. Moreover, 60% of the animals remained tumor-free for
8months. In this model, vaccination-induced B16 cell-specific
CD8 T cells (102).
In summary, although the high expression of CD44 in CSCs,
and other cell types render CD44 as an attractive molecule for a
targeted vaccine therapy, the use of CD44 vaccination has been
confined to pre-clinical studies in very limited number of cancer
and non-cancer models.
CD44 siRNA Delivery
In a few studies, CD44 has been targeted for therapy using
specific siRNAs. A challenge with this approach is the alter-
natively spliced isoforms of CD44. Based on the sequence, the
siRNAs may downregulate only certain CD44 variants. The most
common isoforms targeted by siRNAs are CD44-standard and
CD44v6.Most commonly theseCD44 siRNAshave been delivered
to tumor cells using nanoparticles. For example, biodegradable
poly ,-lactide-co-glycolide acid nanoparticles have been used to
simultaneously deliver CD44 and FAK siRNAs to ovarian cancer
xenografts. Knockdown of both genes reduced tumor growth
by inhibiting angiogenesis and proliferation index in tumors
(103). More recently, a nanoscale-based drug delivery system
was tested to inhibit the growth of an ovarian cancer xenograft
model. The nanoscale delivery system contained a modified
polypropyleniminedendrimer as a carrier, paclitaxel, a synthetic
analog of luteinizing hormone-releasing hormone peptide for
targeting tumor cells, and siRNA targeted to CD44 mRNA. This
dendrimer was able to downregulate CD44 mRNA and protein
expression and inhibit tumor growth without toxicity, suggesting
that the targeted delivery of CD44 siRNA along with chemothera-
peutic agents may be explored for cancer therapy (104). However,
this study did not specify which CD44 isoforms were targeted
by the siRNAs. Delivery of CD44 siRNAs by coating them on
microneedles for self-delivery was shown to reduce the expression
of CD44 in human skin xenografts in immunocompromised mice
(105). Similarly, a CD44v6 targeting siRNA encapsulated into
polyethylene glycol-poly--lysine micelles was shown to accumu-
late into tumor tissues and reduces tumor growth in a pancreatic
xenograft model (106).
Targeting CD44 for Delivering Antitumor
Therapies
SinceCD44 is overexpressed in a variety of tumor cells, HA-coated
self-assembling nanoparticles or liposomes have been tested for
the delivery of siRNAs and/or chemotherapy drugs in pre-clinical
xenograft models. The siRNAs reported so far include those
specific for the multidrug resistance (MDR) protein or proteins
in the apoptosis pathway (e.g., bcl-2, survivin). The advantage of
CD44-targeting HA-coated nanoparticles for siRNA delivery is
that these nanoparticles are biodegradable and reasonably specific
to tumors. For the proper function, encapsulation and stabiliza-
tion of HA-coated nanoparticles, HA has been combined with
various materials including, poly--lysine-graft-imidazole-based
polyplexes (107), lipids of varying carbon chain lengths/nitrogen
content and polyamines (108), protamine sulfate interpolyelec-
trolyte complexes (109), near infrared dyes for imaging (110),
chitosan(CS)-triphosphate (111), poly(dimethylaminoethyl
methacrylate) for cross-linking of siRNAs (112) and polypropy-
lenimine dendrimer (104). Some studies have confirmed that the
uptake of the HA-coated nanoparticles or liposomes by tumor
cells is mediated by HA-receptor mediated internalization. In
these studies, incubation of tumor cells with soluble HA inhibited
uptake of these materials and non-CD44-expressing cells did not
show preference in up-taking the HA-coated liposomes when
compared to the control liposomes (110, 113).
The efficacy of different HA-coated nanoparticles to deliver
siRNAs has been studied in xenograft models, where the pre-
ferred model is a subcutaneous implantation of tumor cells and
intravenous delivery of the nanoparticles. For example, HA-
poly(ethyleneimine)/HA-poly(ethylene glycol) has been used to
deliverMDR1 siRNA to OVCAR8TR (established paclitaxel resis-
tant) tumors. Following the downregulation of P-glycoprotein,
these xenografts become sensitive to paclitaxel treatment (114).
HA nanoparticles have been loaded with a near infrared dye
(amphiphilic carbocyanine dye that strongly absorbs and fluo-
resces in the near infrared region) to visualize the distribution of
HA-coated nanoparticles in various tissues, by live animal imag-
ing. In this study, intravenous delivery of the nanoparticles and
imaging showed that HA-cisplatin nanoparticles had favorable
safety profile for targeted delivery of cisplatin to tumors, while the
HA-poly(ethyleneimine)/HA-poly(ethylene glycol) nanoparticles
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were efficient in delivering the siRNAs (e.g., survivin) to cisplatin
resistant but CD44-overexpressing tumors (110).
In the nanoparticles that deliver the siRNAs, polymeric com-
pounds (e.g., polyethyleneimine or polyethyleneglycol) form ionic
complexes with the siRNAs; however, these nanoparticles are
not stable. To improve stability while retaining biodegradability,
a HA-graft-poly(dimethylaminoethyl methacrylate) nanoparticle
has been designed. In this nanoparticle, siRNAs are cross-linked
via a disulfide linkage (112). These nanoparticles were shown
to efficiently accumulate in the CD44-overexpressing murine
melanoma tumor tissues and the cross-linked siRNAs had 50%
more stability than the uncross-linked siRNAs. One study has
designed nanoparticles involving HA and protamine sulfate inter-
polyelectrolyte complexes for delivering miR-34a to breast cancer
cells in vitro and in theMDAMB231 subcutaneous xenografts. The
nanoparticle delivery of miR-34a reduced tumor growth by 70%
and showed TUNEL positive cells in tumor tissues (109).
For the delivery of anti-cancer drugs such as doxorubicin, a
photochemically triggered cytosolic drug delivery system based
on combining pH-responsive HA nanoparticles containing dox-
orubicin has been developed (98). The pH responsiveness of
these nanoparticles leads to doxorubicin release, and results in
significant antitumor efficacy both in vitro and in vivo. Simi-
larly, paclitaxel loaded hyaluronate-cholanic acid nanoparticles
with FlammaTM-774 fluorescent dye imaging have been used
to track the targeting of these nanoparticles to tumors upon
intravenous injection (115). The nanoparticles showed accumu-
lation and retention up to day 6 in tumors (SCC7 squamous
cell carcinoma model) upon intravenous injection, with little
accumulation in other organs. Furthermore, the Paclitaxel loaded
nanoparticles decreased tumor growth by over 60%, while free
Paclitaxel at the same concentration (5mg/kg) had little effect
on tumor growth. Amphiphilic cholesteryl-succinoyl hyaluronan
(Chol-Suc-HA) conjugates self-assembled into docetaxel-loaded
nanoparticles in the aqueous environment have been evaluated
both in vitro and in vivo. While all docetaxel-loaded Chol-Suc-
HA nanoparticles showed high drug loading, uniform particle
size distribution and stability in vitro, nanoparticles with higher
degree of substitution of the hydrophobicmoiety had significantly
more stability in plasma and antitumor efficacy in breast cancer
xenografts (116). Similarly, mTOR inhibitor rapamycin chemi-
cally conjugated to HA nanoparticles via a novel sustained-release
linker, 3-amino-4-methoxy-benzoic acid was found to slow down
the clearance of rapamycin by 8.8-fold in immunocompetentmice
bearing CD44-positive 4T1.2neu breast cancer cells. In this pre-
clinical model, rapamycin conjugated HA nanoparticle inhibited
tumor growth and increased survival (117).
Hyaluronic acid-coatedmagnetic nanoparticles have been tried
for the delivery of chemotherapeutic drugs to tumors. An advan-
tage of these nanoparticles is their tracking bymagnetic resonance
imaging. In an ovarian cancermodel, the HA-coated superparam-
agnetic iron oxide nanoparticles laded with doxorubicin delayed,
as well as, reduced tumor growth and increased survival (118).
In summary, HA-coated nanoparticles can be conjugated to a
variety of materials for the delivery of siRNAs or chemotherapy
drugs. Although it is clear that the nanoparticles are taken up by
tumor cells or tissues via receptor-medicated endocytosis, it is less
clear whether the nanoparticles are taken up only through CD44-
medidated endocytosis. This is because a variety of tumors also
overexpress RHAMM. Since in most studies, the efficacy of these
nanoparticles has been evaluated in immunocompromised mice,
it is unclear what the distribution will be of these nanoparticles
in an immunocompetent host. The latter is of importance since
CD44 was originally known as a “lymphocyte homing receptor”
and is highly expressed in both B- and T-lymphocytes. However,
since the major (and probably the only) CD44 isoform expressed
in lymphocytes is the standard form, siRNAs specifically directed
to the variant isoforms should have the specificity for targeting
tumors. Nevertheless, the long-term toxicity, stability, and tissue
distribution of the various HA-coated nanoparticles will need to
be evaluated in relevant hosts before these nanoparticles can be
tested in clinical trials.
Targeting of CD44 Protein
The efficacy of anti-CD44 antibodies has been evaluated in
murinemodels of autoimmune and inflammatory diseases includ-
ing thrombocytopenia and arthritis. Immune thrombocytopenia
is an autoimmune bleeding disorder characterized by a lowplatelet
count and the production of anti-platelet antibodies (119, 120).
While the standard treatment for immune thrombocytopenia is
passive infusion of immunoglobulins, several anti-CD44 antibod-
ies have been shown to ameliorate immune thrombocytopenia.
However, some anti-CD44 antibodies (i.e., IM7, IRAWB14.4,
5035-41.1D, KM201, KM114, and KM81), which reduce serum-
induced arthritis can themselves induce thrombocytopenia in
murine models (120). It has been suggested that since CD44 is not
expressed in human platelets, anti-CD44 antibodies should not
induce thrombocytopenia in patients. A fully humanized rat anti-
CD44 monoclonal antibody, PF-03475952 was found to cause
a dose-dependent decrease in symptoms in a mouse model of
collagen-induced arthritis. This monoclonal antibody was found
to be safe in pharmacological assays. The antibody was suggested
as a treatment for inflammatory diseases such as rheumatoid
arthritis (121); however, no further studies were conducted on this
antibody and the antibody does not appear to have entered in clin-
ical trials. In a genome-wide association study, CD44was found to
be a functionally associated gene in type 2 diabetes patients (122).
The same study found that intraperitoneal administration of an
anti-CD44 antibody in a murine model of high fat diet induced
type 2 diabetes, decreased blood glucose levels, and macrophage
infiltration in adipose tissues (123). Furthermore, daily injection
of the anti-CD44 antibody decreased blood glucose levels, weight
gain, liver steatosis, and insulin resistance to the levels lower than
anti-diabetes drugs metformin and pioglitazone (122).
Anti-CD44 antibodies have also been evaluated as an anti-
cancer therapeutic. In chronic lymphocytic leukemia cells, which
express high levels of CD44, a humanized monoclonal antibody
specific for CD44 (RG7356) was found to be cytotoxic to leukemia
B cells without affecting the viability of normal B cells. Systemic
administration of this antibody caused complete clearance of
leukemia xenografts. Interestingly, the effects of the antibody were
not neutralized in the presence of HA, suggesting that CD44 may
have functions other than binding to HA, which play a role in
leukemia (124). The bio-distribution of the same antibody has
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been evaluated in the CD44(+) and CD44( ) xenograft bearing
mice and normal cynomolgus monkeys, following radiolabel-
ing with (89)Zr (125). The study found that while the uptake
of the (89)Zr-RG7356 antibody in CD44+ xenografts was ~9-
fold higher than in CD44( ) xenograft, the uptake in CD44(+)
xenograft was similar, regardless of whether the xenograft was
responsive or non-responsive to the anti-CD44 antibody. Sim-
ilarly, the antibody was detected in the spleen, salivary glands,
and bone marrow, most likely because these organs express high
levels of CD44 (125). Therefore, for targeting tumors a large
dose of an anti-CD44 antibody might be needed and further-
more, simply the presence of the antibody in tumors may not
be indicative of its efficacy. In pancreatic cancer, where CD44
expression correlates with poor prognosis, intravenous delivery
of an anti-CD44 monoclonal antibody H4C4 has been shown to
completely inhibit tumor growth and metastasis in two different
pancreatic xenograft models. In the same study, H4C4 was also
able to eliminate tumor initiating cells, as well as, tumor recur-
rence following radiation treatment. This suggests that targeting of
CD44-overexpressing pancreatic CSCs may improve outcome in
pancreatic cancer patients who undergo radiation therapy (126).
In addition to the therapeutic uses of various anti-CD44
antibodies, a study has used an anti-CD44 antibody for tumor
imaging. For example, a chimeric monoclonal antibody U36
and its F(ab0)2 and Fab0 fragments that recognize the CD44v6
isoform have shown potential for radioimmuno-therapy and
radioimmuno-targeting of experimental tumors (127, 128). A
99mTc-labeled U36, when used in conjugation with a single-
photon emission computed tomography has been shown to
detect all primary tumors of head and neck squamous cell
carcinoma. In clinical trials, this antibody labeled with 186Re-
labeled could detect up to 66% of breast cancer lesions
(129). However, these techniques do not visualize micro-
tumors, tumor nodes with necrosis, or tumors containing
keratin or fibrin. Another humanized anti-CD44v6 antibody
VFF18 labeled with a near infrared dye IRDye800Cw has
shown promise in tracking ductal carcinoma in situ in mouse
xenografts (130).
As in the case of HA-coated nanoparticles or liposomes, anti-
CD44 antibody–drug conjugates have also been used either for
imaging of tumors or for delivering chemotherapeutic agents to
experimental tumor models. For example, anti-CD44 antibody
conjugates have been used to deliver radioisotopes or mertansine
for the treatment of CD44-expressing tumors. In these studies,
disease stabilization was observed in breast or head and neck
tumor patients; however, dose-limiting toxicity was observed
along with the distribution of the antibody in the skin, where
high levels of CD44 are expressed (131). In phase I studies, maxi-
mum tolerated dose, safety, and efficacy of an immuno-conjugate
BIWI 1 (bivatuzumabmertansine), consisting of a highly potent
anti-microtubule agent coupled to an anti-CD44v6 monoclonal
antibody, was evaluated in head and neck cancer patients. In this
study, while three patients showed a partial response, the binding
of BIWI to CD44v6 on skin keratinocytes caused serious skin
toxicity with a fatal outcome, leading to early termination of this
trial (132).More recently, nanoparticles and liposomes containing
an anti-CD44 antibody, as well as, imaging reagents (e.g., cDNAs
for monomeric red fluorescence protein or luciferase) have been
used to target tumor detection and imaging (86). Anti-CD44v6
single chain variable fragment [scFv(CD44v6)] screened out from
the human phage-display library has been used for the targeting
of arsenite ion (As) encapsulated nanoparticles to CD44-positive
cells. Upon intravenous delivery, these nanoparticles specifically
accumulated in the PANC-1 tumor xenografts for up to 2 days and
completely inhibited tumor growth (133). However, none of these
reagents have been evaluated in clinical trials.
The HA binding domain is highly conserved in all CD44
isoforms and, therefore, attempts have been made to target this
domain using specific mono-thiophosphate-modified aptamers.
These aptamers bind specifically to CD44-expressing tumor cells
with high efficacy. However, the in vivo bioavailability of these
aptamers has not been examined in detail (134).
In summary, targeting of CD44 by siRNAs or antibodies for
therapy and the use of HA-coated nanoparticles or of anti-CD44
antibody conjugates for the delivery of therapeutic agents have
been examined as attractive strategies in the treatment of cancer
and chronic diseases. In addition, anti-CD44 antibodies have
also been used for imaging purposes. However, the majority of
the studies are limited to pre-clinical models. In limited clinical
studies, the use of anti-CD44 antibodies has resulted in significant
toxicity. In addition, theHA-coated nanoparticlesmay also deliver
the cargo to tissues, which express other HA receptors. Therefore,
treatment and imaging strategies that target CD44 will have to
be carefully evaluated for their effects on normal cells, and the
immune system. Furthermore, the risk versus benefit must be
carefully evaluated before CD44-targeting strategies are translated
to the clinic.
Conclusion
CD44 is a transmembrane protein with a variety of functions
depending on its ligand binding, co-receptor associations, and
cytoskeletal interaction. The normal functions of LMMHA bind-
ing with CD44 coupled with CD44’s inherent interactions with
secondary signaling complexes allow for wound healing, modu-
lation of the immune system, and developmental angiogenesis.
Irregular or prolonged CD44 and CD44–HA interaction, how-
ever, can lead to fibrosis, scarring, immunopathology, and tumor
growth. The high expression of CD44 and high production of
HA in tumor environments make them both prime targets for
therapeutic intervention. The presence of CD44 at high concen-
trations in the skin and other tissues and the necessity of HA pro-
duction for proper wound healing complicates potential clinical
intervention strategies. Further understanding of the complexities
of CD44 HA-dependent and independent signaling are required
for developing highly specific targeted therapeutics that avoid the
previously seen serious adverse reactions.
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